UPDATE: Medicines Co. (MDCO) Says Milano Study Interim Data Inconclusive - Bloomberg
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
(Updated - August 30, 2016 4:30 PM EDT)
Medicines Co. (NASDAQ: MDCO) said interim analysis of the first 40 patients completing treatment in its Milano-Pilot study didn't meet the pre-defined efficacy threshold to stop early, according to Bloomberg. The company had hoped the analysis would allow early termination of the study, but so far data is "inconclusive."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zimmer Biomet Holdings (ZBH) Announces Statistical Superiority in Seven-Year Follow-up of Mobi-C vs. Two-Level ACDF
- Providence & Worcester (PWX) Receives Shareholder Approval of Genesee & Wyoming (GWR) Deal
- Veracyte (VCYT) Announces Significant Data from Percepta Bronchial Genomic Classifier in Lung Cancer Screening
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!